Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Hematologic Neoplasms 1

Interventions

Cyclophosphamide 678Cytarabine 576fludarabine 410fludarabine phosphate 387venetoclax 310Methotrexate 297Rituximab 283Azacitidine 264Busulfan 248Whole-Body Irradiation 220Etoposide 215Filgrastim 214Peripheral Blood Stem Cell Transplantation 211Mycophenolic Acid 206Tacrolimus 196Dexamethasone 191Granulocyte Colony-Stimulating Factor 182Vincristine 173Melphalan 173Decitabine 163Cyclosporine 146Daunorubicin 139Antilymphocyte Serum 137Idarubicin 134Imatinib Mesylate 127Lenalidomide 116Doxorubicin 109Radiotherapy 108Stem Cell Transplantation 107Clofarabine 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Maraviroc × Other hematologic neoplasm × Clear all
NCT01785810 2021-01-11

Phase II Maraviroc for GVHD Prevention

Abramson Cancer Center at Penn Medicine

Phase 2 Completed
37 enrolled 17 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡